Cytokinetics

YTD

ALL

Trade Cytokinetics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.

CEO

Robert I. Blum

CEORobert I. Blum

Employees

673

Employees673

Headquarters

South San Francisco, California

HeadquartersSouth San Francisco, California

Founded

1997

Founded1997

Employees

673

Employees673

CYTK Key Statistics

Market cap

10.10B

Market cap10.10B

Price-Earnings ratio

-11.87

Price-Earnings ratio-11.87

Dividend yield

—

Dividend yield—

Average volume

2.34M

Average volume2.34M

High today

$81.25

High today$81.25

Low today

$81.25

Low today$81.25

Open price

$80.53

Open price$80.53

Volume

263.00

Volume263.00

52 Week high

$82.83

52 Week high$82.83

52 Week low

$32.63

52 Week low$32.63

Stock Snapshot

The current Cytokinetics(CYTK) stock price is $81.25, with a market capitalization of 10.1B. The stock trades at a price-to-earnings (P/E) ratio of -11.87.

On 2026-06-25, Cytokinetics(CYTK) stock traded between a low of $81.25 and a high of $81.25. Shares are currently priced at $81.25, which is 0.0% above the low and 0.0% below the high.

Cytokinetics(CYTK) shares are trading with a volume of 263, against a daily average of 2.34M.

During the past year, Cytokinetics(CYTK) stock moved between $32.63 at its lowest and $82.83 at its peak.

CYTK News

TipRanks 1d

Cytokinetics price target raised to $118 from $100 at Mizuho

Mizuho raised the firm’s price target on Cytokinetics (CYTK) to $118 from $100 and keeps an Outperform rating on the shares. The firm updated the company’s mode...

TipRanks 1d

Top Cytokinetics Exec Makes Bold Move With Fresh Insider Stock Sale

New insider activity at Cytokinetics ( (CYTK) ) has taken place on June 23, 2026. TipRanks' Prime Week Sale - 70% Off Unlock powerful investing tools and data-d...

Investing.com 3d

Cytokinetics stock reaches 52-week high at 80.25 USD - Investing.com

...

Analyst ratings

91%

of 22 ratings

Buy

90.9%

Hold

9.1%

Sell

More CYTK News

Simply Wall St 6d

Cytokinetics Stock Could Be 15% Undervalued After Myqorzo Approval

Cytokinetics (CYTK) is back in focus after the FDA cleared its first commercial product, Myqorzo, for symptomatic obstructive hypertrophic cardiomyopathy, with...

People also own

Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.